Federal contract award
75FCMC21F0090
END-STAGE RENAL DISEASE (ESRD) QUALITY INCENTIVE PROGRAM (QIP) MONITORING AND EVALUATION (M&E)
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | OFC OF ACQUISITION AND GRANTS MGMT |
| NAICS | 541611 — Administrative Management and General Management Consulting Services |
| PSC | R499 — Other Professional Services |
| Parent award / vehicle | GS10F0136X |
| Set-aside | 8A COMPETED |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $6.2M |
| Current contract value | $6.2M |
| Potential contract value / ceiling | $6.2M |
| Start date | Sep 12, 2021 |
| Current end date | Mar 11, 2027 |
| Potential end date | Mar 11, 2027 |
| Latest award activity | Sep 9, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 10 of 10 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 9, 2026 | P00009 | $398.1K | END-STAGE RENAL DISEASE (ESRD) QUALITY INCENTIVE PROGRAM (QIP) MONITORING AND EVALUATION (M&E) |
| Sep 9, 2025 | P00008 | $1.2M | END-STAGE RENAL DISEASE (ESRD) QUALITY INCENTIVE PROGRAM (QIP) MONITORING AND EVALUATION (M&E) |
| Oct 9, 2024 | P00007 | $0 | END-STAGE RENAL DISEASE (ESRD) QUALITY INCENTIVE PROGRAM (QIP) MONITORING AND EVALUATION (M&E) |
| Aug 13, 2024 | P00006 | $1.1M | END-STAGE RENAL DISEASE (ESRD) QUALITY INCENTIVE PROGRAM (QIP) MONITORING AND EVALUATION (M&E) |
| Oct 18, 2023 | P00005 | $0 | END-STAGE RENAL DISEASE (ESRD) QUALITY INCENTIVE PROGRAM (QIP) MONITORING AND EVALUATION (M&E) |
| Aug 14, 2023 | P00004 | $1.2M | END-STAGE RENAL DISEASE (ESRD) QUALITY INCENTIVE PROGRAM (QIP) MONITORING AND EVALUATION (M&E) |
| Aug 2, 2022 | P00003 | $1.1M | END-STAGE RENAL DISEASE (ESRD) QUALITY INCENTIVE PROGRAM (QIP) MONITORING AND EVALUATION (M&E) |
| Mar 7, 2022 | P00002 | $0 | END-STAGE RENAL DISEASE (ESRD) QUALITY INCENTIVE PROGRAM (QIP) MONITORING AND EVALUATION (M&E) |
| Nov 4, 2021 | P00001 | $0 | END-STAGE RENAL DISEASE (ESRD) QUALITY INCENTIVE PROGRAM (QIP) MONITORING AND EVALUATION (M&E) |
| Sep 8, 2021 | 0 | $1.1M | END-STAGE RENAL DISEASE (ESRD) QUALITY INCENTIVE PROGRAM (QIP) MONITORING AND EVALUATION (M&E) |
Estimated positioning window
Oct 25, 2026 – Jan 23, 2027
75/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 75/100. Available recorded signals: 70 points.
- Contract end 2027-03-11 (137 days from calculation)
- +35 points
- 222 historical awards in this buyer and category group
- +15 points
- 10 recorded award transactions
- +10 points
- Latest award action: 2026-09-09
- +5 points
- Parent award identifier recorded
- +5 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.